Chemoenzymatic ligation FAQ

Hongene's Chemoenzymatic Ligation FAQ details a breakthrough in RNA drug manufacturing:

• Technology Core: Enzymatic ligation of chemically synthesized fragments (blockmers) replaces traditional SPOS, solving high cost, high waste, and low purity (SPOS consumes 3,000kg raw material/kg API with ~90% purity).
• Key Advantages:
  • High Purity: siRNA purity ≥97% (vs. SPOS ~90%), impurities <1.0%;
  • High Efficiency: Yield up to 40-50% (vs. SPOS ~50%), eliminates chromatography;
  • Sustainability: Water-based reactions reduce raw material use by 99%, supports full chemistries (GalNAc, 2'-OMe, etc.).
• Clinical Validation: Successfully produced PCSK9 siRNA (e.g., Inclisiran) for cardiovascular drug development, enabling >10 tons of siRNA API demand by 2030.
• Industry Impact: Delivers a scalable, reliable, and eco-friendly platform for siRNA/sgRNA, accelerating RNA therapeutic commercialization.

Download the flyer for full mass spectrometry data, impurity control profiles, and process details.